Showing results (11-20 of 85) with videos related to

Sort By:
Pageof 9
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|December 8, 2021
Refractory cytokine release reaction to Nivolumab: Following desensitization algorithms to optimize the management of drug hypersensitivityLaura Sánchez Togneri, Ignacio Duran, Fernando Rodríguez Fernández, et al.
Urology|August 30, 2021
A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable RiskAdi Kartolo, Ryan G Holstead, Ignacio Duran, et al.
European Journal of Haematology|February 15, 2018
Healthcare resource utilisation associated with skeletal-related events in European patients with multiple myeloma: Results from a prospective, multinational, observational studyJohn Ashcroft, Ignacio Duran, Herbert Hoefeler, et al.
World Journal of Surgical Oncology|December 17, 2009
Isolated recurrence of distal adenocarcinoma of the extrahepatic bile duct on a draining sinus scar after curative resection: case report and review of the literatureJesús Rodríguez-Pascual, Emilio De Vicente, Yolanda Quijano, et al.
Oncotarget|January 2, 2018
Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinomaCarmen Garrigós, Marta Espinosa, Ana Salinas, et al.
Expert Opinion on Drug Safety|February 13, 2014
Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanismsIgnacio Duran, Peter-Jürgen Goebell, Konstantinos Papazisis, et al.
Clinical Pharmacokinetics|April 28, 2020
Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate CancerIgnacio Duran, Joan Carles, Iurie Bulat, et al.
Molecular and Clinical Oncology|July 24, 2014
Health resource utilisation associated with skeletal-related events in European patients with lung cancer: Α subgroup analysis from a prospective multinational studyVito Lorusso, Ignacio Duran, Cristina Garzon-Rodriguez, et al.
Oncotargets and Therapy|October 25, 2017
Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanibKonstantinos Koutsoukos, Aristotelis Bamias, Kimon Tzannis, et al.
Urologic Oncology|February 22, 2020
MicroRNAs as potential predictors of extreme response to tyrosine kinase inhibitors in renal cell cancerCarmen Garrigós, Sonia Molina-Pinelo, Ricardo Meléndez, et al.
Pageof 9